Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Autologous dendritic cell based adoptive immunotherapy of patients with colorectal cancer-A phase I-II study.

Hunyadi J, András C, Szabó I, Szántó J, Szluha K, Sipka S, Kovács P, Kiss A, Szegedi G, Altorjay I, Sápy P, Antal-Szalmás P, Tóth L, Fazekas G, Rajnavölgyi É.

Pathol Oncol Res. 2014 Apr;20(2):357-65. doi: 10.1007/s12253-013-9704-3. Epub 2013 Oct 28.

PMID:
24163303
2.

Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells.

Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehninger G, Schmitz M, Bornhäuser M.

Cancer Immunol Immunother. 2006 Mar;55(3):268-76. Epub 2005 Jul 21.

PMID:
16034561
3.

Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.

Lesterhuis WJ, De Vries IJ, Schreibelt G, Schuurhuis DH, Aarntzen EH, De Boer A, Scharenborg NM, Van De Rakt M, Hesselink EJ, Figdor CG, Adema GJ, Punt CJ.

Anticancer Res. 2010 Dec;30(12):5091-7.

PMID:
21187495
4.

Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors.

Tamir A, Basagila E, Kagahzian A, Jiao L, Jensen S, Nicholls J, Tate P, Stamp G, Farzaneh F, Harrison P, Stauss H, George AJ, Habib N, Lechler RI, Lombardi G.

Cancer Immunol Immunother. 2007 Dec;56(12):2003-16. Epub 2007 Feb 23.

PMID:
17333181
5.

Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.

Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L.

J Immunother. 2007 Oct;30(7):762-72.

PMID:
17893568
6.

A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment.

Liu KJ, Chao TY, Chang JY, Cheng AL, Ch'ang HJ, Kao WY, Wu YC, Yu WL, Chung TR, Whang-Peng J.

J Biomed Sci. 2016 Aug 24;23(1):64. doi: 10.1186/s12929-016-0279-7.

7.

Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.

Koido S, Hara E, Homma S, Torii A, Toyama Y, Kawahara H, Watanabe M, Yanaga K, Fujise K, Tajiri H, Gong J, Toda G.

Clin Cancer Res. 2005 Nov 1;11(21):7891-900.

10.

The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity.

Park MY, Kim CH, Sohn HJ, Oh ST, Kim SG, Kim TG.

Vaccine. 2007 Oct 16;25(42):7322-30. Epub 2007 Sep 6.

PMID:
17889413
11.

Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells.

Michalek J, Hezova R, Turanek-Knötigova P, Gabkova J, Strioga M, Lubitz W, Kudela P.

Cancer Immunol Immunother. 2017 Feb;66(2):149-159. doi: 10.1007/s00262-016-1932-4. Epub 2016 Nov 18.

PMID:
27864613
12.

Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests.

Lesterhuis WJ, de Vries IJ, Schuurhuis DH, Boullart AC, Jacobs JF, de Boer AJ, Scharenborg NM, Brouwer HM, van de Rakt MW, Figdor CG, Ruers TJ, Adema GJ, Punt CJ.

Ann Oncol. 2006 Jun;17(6):974-80. Epub 2006 Apr 6.

PMID:
16600979
13.

Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.

Hobo W, Strobbe L, Maas F, Fredrix H, Greupink-Draaisma A, Esendam B, de Witte T, Preijers F, Levenga H, van Rees B, Raymakers R, Schaap N, Dolstra H.

Cancer Immunol Immunother. 2013 Aug;62(8):1381-92. doi: 10.1007/s00262-013-1438-2. Epub 2013 Jun 2.

PMID:
23728352
14.

Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide.

Sakakibara M, Kanto T, Hayakawa M, Kuroda S, Miyatake H, Itose I, Miyazaki M, Kakita N, Higashitani K, Matsubara T, Hiramatsu N, Kasahara A, Takehara T, Hayashi N.

Cancer Immunol Immunother. 2011 Nov;60(11):1565-75. doi: 10.1007/s00262-011-1051-1. Epub 2011 Jun 17.

PMID:
21681375
15.

Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.

Morisaki T, Matsumoto K, Onishi H, Kuroki H, Baba E, Tasaki A, Kubo M, Nakamura M, Inaba S, Yamaguchi K, Tanaka M, Katano M.

Hum Cell. 2003 Dec;16(4):175-82. Review.

PMID:
15147037
16.

Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.

Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK.

Clin Cancer Res. 2005 Apr 15;11(8):3017-24.

17.

Induction of antigen-specific CD4- and CD8-mediated T-cell responses by fusions of autologous dendritic cells and metastatic colorectal cancer cells.

Koido S, Hara E, Torii A, Homma S, Toyama Y, Kawahara H, Ogawa M, Watanabe M, Yanaga K, Fujise K, Gong J, Toda G.

Int J Cancer. 2005 Nov 20;117(4):587-95.

18.

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.

Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.

J Immunother. 2006 Sep-Oct;29(5):545-57.

PMID:
16971810
19.

Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.

Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M.

J Immunol. 2000 Apr 1;164(7):3902-12.

20.

Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells.

Koido S, Hara E, Homma S, Torii A, Mitsunaga M, Yanagisawa S, Toyama Y, Kawahara H, Watanabe M, Yoshida S, Kobayashi S, Yanaga K, Fujise K, Tajiri H.

J Immunol. 2007 Jan 1;178(1):613-22.

Supplemental Content

Support Center